Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Re-Evaluation

Congestive Heart Failure

Volumn 18, Issue 4, 2012, Pages 229-233

  Varma, Amit ^a   Shah, Keyur B ^a   Hess, Michael L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXIMONE; FLOSEQUINAN; HYDRALAZINE; ISOSORBIDE DINITRATE; MILRINONE; NESIRITIDE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PIPERANOMETOZINE; PLACEBO; SILDENAFIL;

ADULT; ARTIFICIAL HEART PACEMAKER; CASE REPORT; CONGESTIVE HEART FAILURE; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MEDICAL HISTORY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

ADULT; DEATH, SUDDEN, CARDIAC; DRUG INTERACTIONS; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RISK FACTORS; STROKE VOLUME; SULFONES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 84864069436     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2012.00293.x     Document Type: Review

References (29)

1. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56:453-459.
2. Corbin JD, Francis SH. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. 2002;60(2 suppl 2):4-11.
3. Uzunov P, Weiss B. Separation of multiple molecular forms of cyclic adenosine 3′5′ monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis. Biochem Biophys Acta. 1972;284:220-226.
4. Fertel R, Weiss B. Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung. Mol Pharmacol. 1976;12:678-687.
5. Morgan JP, Gwathmey JK, DeFeo TT, et al. The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle. Circulation. 1986;73(3 pt 2):III65-III77.
6. Hastillo A, Hess M, Taylor DO. Amrinone. In: Massarelli F, ed. Cardiovascular Therapeutics, 1st ed. Philadelphia, PA: W.B. Saunders; 1996:300-315.
7. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 1990;82:774-780.
8. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
9. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1992;329:149-155.
10. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
11. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;CD002230.
12. Alpaslan M, Onrat E, Samli M, et al. Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. Ann Noninvasive Electrocardiol. 2003;8:14-17.
13. Beasley CM Jr, Mitchell MI, Dmitrienko AA, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol. 2005;46:678-687.
14. Morganroth J, Ilson BE, Shaddinger BC, et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol. 2004;93:1378-1383.
15. Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation. 2000;102:275-277.
16. Chiang CE, Luk HN, Wang TM, et al. Effects of sildenafil on cardiac repolarization. Cardiovasc Res. 2002;55:290-299.
17. Roden DM. Acquired long QT syndrome and the risk of proarrhythmia. J Cardiovasc Electrophysiol. 2000;11:938-940.
18. Dustan Sarazan R, Crumb WJ Jr, Beasley CM Jr, et al. Absence of clinically important hERG channel blockade by three compounds that inhibit phosphodiesterase-5 - sildenafil, tadalafil, and vardenafil. Eur J Pharmacol. 2004;502:163-167.
19. Swissa M, Ohara T, Lee MH, et al. Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. Am J Physiol Heart Circ Physiol. 2002;282:H1787-H1792.
20. Kanlop N, Shinlapawittayatorn K, Sungnoon R, et al. Sildenafil citrate on the inducibility of ventricular fibrillation and upper limit of vulnerability in swine. Med Sci Monit. 2008;14:BR205-BR209.
21. Shinlapawittayatorn K, Sungnoon R, Chattipakorn S, et al. Effects of sildenafil citrate on defibrillation efficacy. J Cardiovasc Electrophysiol. 2006;17:292-295.
22. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144.
23. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1year study. Circulation. 2011;124:164-174.
24. Evaluating the effectiveness of sildenafil of improving health outcomes and exercise ability in people with diastolic heart failure - The RELAX Study. 2011; Available at:. Accessed November 29, 2011.
25. Shah PK. Sildenafil in the treatment of ED. N Engl J Med. 1998;339:699.
26. Awan GM, Calderon E, Dawood G, et al. Acute, symptomatic atrial after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2000;320:69-71.
27. Hahn IH, Hoffman RS. Aroused to atrial fibrillation? Am J Emerg Med. 2000;18:642.
28. Rasmussen JG, Toft E, Frøbert O. Ventricular tachycardia after administration of sildenafil citrate: a case report. J Med Case Reports. 2007;1:65.
29. Franciosa JA, Taylor AL, Cohn JN, et al. African American Heart Failure Trial (A-HeFT): rationale, design and methodology. J Card Fail. 2002;8:128-135.